Oneness Biotech Co., Ltd.

This study tests a drug called FB825 in adults with moderate-to-severe atopic dermatitis (eczema). Participants receive five injections over 12 weeks, either FB825 or a placebo, to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment opti…

This study tests whether a new drug, FB825, can help adults with moderate-to-severe allergic asthma. About 100 participants will receive either FB825 or a placebo. The main goal is to see if FB825 reduces asthma attacks over 24 weeks.

This early-stage study is testing a new drug, SNS851, in 52 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo by injection. The goal is to check for side effects, not to treat any disease.